Eli Lilly said the FDA is expected to decide on its oral obesity pill orforglipron in the second quarter of 2026 after granting Lilly a national priority review voucher intended to accelerate evaluation. Lilly plans a rapid review and a near‑term launch to compete with Novo Nordisk’s newly launched Wegovy pill. Separately, the FDA requested removal of suicidal‑ideation warnings from GLP‑1 obesity drug labels after post‑market review found no increased risk. That regulatory clarity reduces a label uncertainty for manufacturers and may affect risk communications as both injectable and oral GLP‑1 agents scale rapidly in the market.